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Abstract
Background: The rising co-epidemic of tuberculosis (TB) and diabetes mellitus (DM) is a challenge for constrained
health systems in low and middle-income countries. Diabetes is a known risk factor for tuberculosis and associated
with poor tuberculosis treatment outcomes, while tuberculosis is associated with worsening glycemic control. We
investigated the performance of bi-directional TB and DM case finding approaches through a private-sector
engagement model in Karachi, Pakistan.
Methods: Between July 2016 and July 2018, private health care providers were engaged to generate referrals for
bi-directional TB and DM screening at private diagnostic and treatment centers in Karachi, Pakistan. Individuals
diagnosed with TB underwent glycated hemoglobin (HbA1c) testing at the time of anti-tuberculous treatment
initiation and at three -month follow up stage. All individuals with a history of diabetes or random blood sugar of
greater than 200 mg/dl were screened for TB using a chest X-ray and Xpert MTB/RIF.
Results: A total of 6312 persons with tuberculosis were tested on HbA1c at treatment initiation, of whom 1516
(24%) were newly diagnosed with DM. About one third of those with HbA1c in the diabetic range (≥ 6.5%) at
baseline were found to have a normal HbA1c (< 5.7%) result at 3-month follow-up. A total of 3824 individuals with
DM, of whom 2396 (63%) were known cases and 1428 (37%) were newly identified with random blood sugar >
200 mg/dl, underwent chest x-ray and Xpert MTB/RIF testing, with 321 (13.4%) known and 54 (3.8%) new diabetics
respectively identified with tuberculosis.
Conclusion: This study demonstrates a high yield of TB and DM through bidirectional screening and the feasibility
of engagement of private sector in finding missing cases of tuberculosis and diabetes. Given the high prevalence of
undiagnosed DM in individuals with TB tuberculosis patients, there is a need to scale-up DM screening within TB
programmes. Increased awareness of the high risk of TB among individuals with DM is needed among private
health providers and screening for TB among diabetics should be strongly considered.
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Background
The global burden of Diabetes Mellitus (DM) has dou-
bled from 1980 to 2017, posing a significant economic
burden on health systems globally [1]. The International
Diabetes Federation has estimated that the number of
people living with DM worldwide will rise from 463 mil-
lion in 2019 to 700 million by 2045 [2]. Tuberculosis
(TB) remains the leading cause of death from a single in-
fectious agent with an estimated 1.5 million deaths in
2018 [3].
There is increased recognition of the synergy between
DM and TB [4, 5]. Currently, an estimated 1 million
people globally are present with TB-DM comorbidity,
higher than the number of patients with TB-HIV co-
infection [4]. DM increases the risk of developing TB
three-fold and is associated with delayed sputum conver-
sion, treatment failure, relapse and death [6]. TB in turn
is associated with worsening glycemic control.
Based on available evidence, the International Union
against TB and Lung Disease launched a Call to Action in
2014 that emphasized upon the significance of bi-
directional screening and joint management of TB and
DM [7]. However, implementation of these recommenda-
tions has been challenging in countries such as Pakistan
where the private sector contributes to a majority of
health services delivery. There have been very limited
private-sector engagement initiatives that have addressed
the dual burden of TB and DM. We piloted a bi-
directional screening project that developed a network of
trained private-providers, linked to diagnostic and treat-
ment centers for improved patient outcomes [8].
In this study we investigated the outcomes of the
scale-up of a TB-DM bi-directional screening program
in the private-sector in Karachi, Pakistan, modelled on
the World Health Organization’s (WHO) Collaborative
Framework for care and control of tuberculosis and dia-
betes [9]. In addition to expanding the geographic cover-
age of the program, our current study also addresses the
limitation of the pilot by using glycated hemoglobin
(HbA1c) instead of random blood sugar (RBS) test as
the diagnostic test for DM among individuals with TB.
Methods
Study setting and design
A retrospective cross sectional study in which, bidirec-
tional screening for TB and DM was offered to clients
attending private TB diagnostic and treatment centers
“Sehatmand Zindagi (SZ) (healthy life) centers and com-
munity screening camps in Karachi, Pakistan between
July 2016 and July 2018. Karachi is Pakistan’s most
populous city and the country’s economic hub with an
estimated 75% of all health services availed in the private
sector [10]. Pakistan has the fourth highest burden of
DM globally with a current estimated prevalence of
17.1% in the adult population. An estimated 8.5 million
adults are living with undiagnosed DM [2]. Pakistan is
also ranked fifth among high tuberculosis burden coun-
tries with an estimated 36% case notification gap [3].
The SZ centers, located in low middle income neigh-
borhoods of Pakistan operate as a social business, pro-
viding free TB diagnostics, chest X-ray and Xpert MTB/
RIF, and treatment. Revenue is generated through other
laboratory tests and radiology services. All TB cases are
notified to the National TB Control Program (NTP).
Each center has established linkages with other health
providers in the vicinity including those in the informal
health sector. The center has a dedicated team who en-
gage private health providers and facilitate referral of in-
dividuals with presumptive TB to the centers. Clients
are also able to self-refer to centers. Community based
screening camps are conducted by trained community
health workers employing mobile X- ray vans.
Recruitment of individuals with TB for DM testing
Individuals presenting at SZ Centers and screening
camps with a previous history of TB or with signs and
symptoms of TB were referred to the TB arm of
screening where they were tested for DM if TB diag-
nosis was established. TB screening was conducted
using digital chest X- rays with CAD4TB 5 (version
4.12.0) software for automated scoring Individuals
with presumptive TB were defined as those with a
threshold CAD4TB score of 70, who then submitted a
sputum sample for Xpert MTB/RIF testing. A positive
Xpert MTB/RIF testing result or a strong indication
at clinical evaluation of the CXR and symptoms lead
to the diagnosis of bacteriologically positive or clinical
TB respectively. All individuals identified with TB
underwent HbA1c testing at anti-tuberculous treat-
ment (ATT) initiation. Those who gave consent also
had a 3-month HbA1c follow up. According to the
recommendation of 2009 American Diabetes Associ-
ation (ADA), an HbA1c < 5.7% is classified as normal,
5.7–6.4% as pre-diabetes, and ≥ 6.5% as diabetes [11].
Individuals who were diagnosed with diabetes at the
SZ Center were counselled and referred to their gen-
eral practitioner for further management.
Recruitment of individuals with DM for TB testing
Individuals attending the community camps and SZ
Centers were verbally screened for history of diabetes.
Those identified with DM or those presenting with signs
and symptoms of DM were referred to the DM arm of
screening where they were subsequently tested for TB if
DM was diagnosed. If no known history of DM was
found, they were offered a point of care glucose test. In-
dividuals with an RBS > 200 mg/dl or history of diabetes,
were tested on chest X-ray and Xpert MTB/RIF.
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Data management and analysis
We analyzed retrospective data of 10,136 Individuals
who participated in the TB-DM bidirectional screening
project funded by the World Diabetes Foundation.
Under this project, data was recorded using a custom-
built mobile-phone application at community camps, A
customized web-based laboratory management system
(LMS) software was used to book tests and enter screen-
ing data at the centers. Both the mobile and web-based
applications were integrated with the Central Manage-
ment Information System with auto generated reports to
track key project metrics. The data recording and
reporting systems included several data validation checks
to ensure data-accuracy. Field supervisors and project
management staff were responsible for overall data-
validation and accuracy including reporting to the NTP.
Baseline characteristics of participants were described
using means and medians and the prevalence of DM
and TB were calculated. The association of outcomes
(DM and TB) with a prior defined factor was explored
using logistic regression. A comparative frequency ana-
lysis was conducted for HbA1c values at baseline and
after 3 months of ATT for a subset of TB patients. All
data was analyzed using Stata version 13.0 (StataCorp,
Texas, USA).
Ethical approval and consent
An ethical approval was deemed unnecessary for this
study by The Institutional Review Board (IRB) at Inter-
active Research and Development (IRD) under the IRB
exemption category 7 under 45 CFR 46.101(b). The IRB
is registered with the U.S. Department of Health and
Human Services (DHHS), Office for Human Research
Protections (IRB#00005148). A Verbal consent was ob-
tained from participants before conducting blood glu-
cose, HbA1c and Xpert MTB/RIF tests. This study was
part of a larger study (IRB approval number IRD_IRB_
2016_08_001). De-identified data from the project was
used for data analysis.
Results
Diabetes screening in individuals with TB using
glycosylated hemoglobin (Hba1c) testing
A total of 5032 individuals had a positive Mycobacterium
tuberculosis (MTB) result on Xpert MTB/RIF testing,
while 5711 were identified with clinical TB (Fig. 1). Of
these, 6312 were tested for DM using HbA1c. The
Fig. 1 Uptake of diabetes screening among individuals with tuberculosis
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uptake of HbA1c testing was 59.8 and 57.8% in persons
with bacteriologically positive and clinical TB respect-
ively (Fig. 1). A majority (5093) were new TB cases.
Among those screened for DM, 2041 (32%) had pre-
diabetes and 1516 (24%) had newly diagnosed DM
(Table 1). Of those newly diagnosed with DM 25% were
male and 35% were aged 40–59 years. The number
needed to test (NNT) to make one DM diagnosis among
individuals with TB was 4.16 (Table 1).
Screening for TB among individuals with diabetes using
Xpert MTB/RIF testing
A total of 3824 individuals with DM underwent screen-
ing for TB at the SZ centers (Fig. 2). Of these, 1428
(37%) had an RBS greater than 200mg/dl on point of
care testing and 2396 (63%) had a known diagnosis of
DM (Fig. 2). A majority were males and were aged 40–
59 years (Table 2). Among those referred from commu-
nity camps and partner providers, 66.6 and 52.2% re-
spectively were known DM screened for TB whereas,
33.4 and 47.8% respectively were individuals with RBS >
200 mg/dl. The uptake of Xpert MTB/RIF testing among
individuals with RBS > 200 mg/dl and known DM was 76
and 77% respectively (Fig. 2). Of the total individuals
with TB detection, 85.6% were known cases of DM and
14.4% were individuals with an RBS > 200 mg/dl who
underwent Xpert testing (Table 2).
Known diabetes (OR 4.63, CI 3.21–6.66) was the
strongest associated factor in final adjusted models for
MTB detection (Table 3).
Follow-up HbA1c testing for individuals with TB
Among individuals with TB tested on HbA1C at the
ATT initiation, 1077 individuals also underwent follow-
up HbA1c testing after 3 months and 514 (47.7%) had
an unchanged HbA1c range between the baseline and
follow-up tests.
Among the 244 individuals with an HbA1c ≥ 6.5% at
baseline 64(26%) and 77(32%) had anHbA1c that
dropped to 5.7–6.4 and < 5.6% respectively at 3 months.
Of the 331 persons with HbA1c in the pre-diabetes
range at baseline, 148 (44%) dropped to < 5.6% at 3
months. Of the 502 patients with HbA1c < 5.6% at base-
line, 213 (42%) had increased HbA1c ≥ 5.7% at follow-
up (Fig. 3).
Discussion
This study describes findings from the first bi-
directional screening programs for TB and DM carried
out at scale in the private sector. This project was in-
novative in its use of CAD4TB for TB screening and the
use of HbA1c for initial screening of DM among TB
patients.
As in other studies [12–15], we report a high preva-
lence of TB among persons with DM. We also found
that the odds of developing TB were nearly 4.5 times
higher in persons with previously diagnosed DM com-
pared to those who were newly diagnosed. It is possible
that chronic hyperglycemia may be associated with an
increased risk for developing TB. A recent study showed
increased TB risk with duration of DM, with a median
Table 1 Baseline characteristics of individuals with TB tested for diabetes using HbA1c and numbers needed to test (NNT) to
identify one case of diabetes
Total TB Cases Tested for DM
n (%)
Normal
n (%)
Pre-Diabetes
n (%)
Newly Diagnosed DM cases
n (%)
NNT‡ P Value
Total 6312 2755 (44%) 2041 (32%) 1516 (24%) 4.16
Sex
Male 3347 1461 (43.7%) 1052 (31.4%) 834 (24.9%) 4.01 0.122
Female 2965 1294 (43.6%) 989 (33.4%) 682 (23%) 4.35
Age (years)
15–20 885 462 (52.2%) 318 (35.9%) 105 (11.9%) 8.43 < 0.001
20–39 2407 1309 (54.4%) 739 (30.7%) 359 (14.9%) 6.70
40–59 1750 593 (33.9%) 544 (31.1%) 613 (35%) 2.85
> 60 1270 391 (30.8%) 440 (34.6%) 439 (34.6%) 2.92
TB diagnosis
MTB+ 3009 1269 (42.2%) 1024 (34%) 716 (23.8%) 4.20 0.017
Clinically diagnosed 3303 1486 (45%) 1017 (30.8%) 800 (24.2%) 4.13
Past History of TB
No (New case) 5093 2226 (43.7%) 1649 (32.4%) 1218 (23.9%) 4.18 0.927
Yes (Re-treatment 1219 529 (43.4%) 392 (32.2%) 298 (24.4%) 4.09
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Fig. 2 Uptake of tuberculosis screening among individuals with diabetes
Table 2 Baseline characteristics of individuals with previously diagnosed diabetes and those identified with RBS > 200mg/dl
through screening in the private-sector in Karachi, Pakistan, from July 2016 to July 2018
Total
n (%)
RBS > 200
n (%)
Known case of DM
n (%)
p-value
Sex 3824 1428 (37.3%) 2396 (62.7%) < 0.005
Male 2202 777 (35.3%) 1425 (64.7%)
Female 1622 651 (40.1%) 971 (59.9%)
Age < 0.001
15–20 85 46 (54.1%) 39 (45.9%)
20–39 673 328 (48.7%) 345 (51.3%)
40–59 1892 696 (36.8%) 1196 (63.2%)
> 60 1175 358 (30.5%) 817 (69.5%)
Source of referral < 0.001
Community Camps 1288 430 (33.4%) 858 (66.6%)
Others (hospitals, NGOs) 331 108 (32.6%) 223 (67.4%)
Sefl-referred 903 268 (29.7%) 635 (70.3%)
Private provider 1302 622 (47.8%) 680 (52.2%)
TB diagnosis < 0.001
No TB detected 3449 1373 (39.8%) 2076 (60.2%)
MTB + ve 241 28 (11.6%) 213 (88.4%)
Clinical diagnosis 134 26 (19.4%) 108 (80.6%)
Total TB 375 54 (14.4%) 321 (85.6%)
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time to diagnosis for TB of 7 years among those with
DM [16].
Individuals with TB were screened for DM using
Hba1c. The prevalence identified in our study of pre-
DM (32%) and DM (24%) was much higher among indi-
viduals with TB than in the general population of
Pakistan (17%) [2]. This is consistent with findings from
other studies that have reported a high prevalence of up
to 35% of DM in TB patients [17]. The susceptibility of
older individuals to TB and DM in our study is also con-
sistent with previous studies highlighting the risk and
the need for regular screening among older individuals
[18–20]. HbA1c testing was repeated for subset of TB
patients after 3 months of ATT. Transient hyperglycemia
is a common finding among people with TB, with
HbA1c levels reverting to the euglycemic range after 3
months of TB treatment [5, 21]. The cause of transient
hyperglycemic status is likely multifactorial and due to a
combination of inflammation induced by TB, the hyper-
glycemic effect of ATT, and individual risk of DM [21].
Transient hyperglycemia in individuals with TB makes it
challenging to determine the appropriate time for
screening to avoid misdiagnosis of DM. Our data sug-
gests that screening at 3-month follow-up may be more
appropriate than at ATT initiation, although further
drop in Hba1c by end of ATT completion cannot be
excluded. However, this needs to be balanced against the
risk of potential lost to follow-up. The Union also rec-
ommends a follow-up HbA1c at treatment completion
to avoid the risk of overdiagnosis of DM [6].
Our study supports the need to scale-up DM testing
in existing TB programmes. An advocacy meeting facili-
tated by our group with stakeholders from NTP, the
Diabetes Association Pakistan, the Ministry of Health
and other policy makers endorsed recommendations to
conduct routine screening for DM among TB patients at
TB Basic Management Units (BMUs). These measures
are being included as part of the National Strategic Plan
for TB control in Pakistan for implementation at the
district-level. Pakistan has a well-organized vertical TB
program with over 1360 BMUs that provide standard-
ized data surveillance and reporting [22]. Indicators for
DM screening can feasibly be added within the existing
reporting framework. Similar resources are also planned
for allocation for provision of diagnostic services for
public-private mix (PPM) implementing partners of the
NTP, targeting the private sector.
With an estimated 19.4 million adults with DM in
Pakistan, there is an important opportunity for finding
undiagnosed cases of TB by incorporating TB screening
within DM services [2]. Lack of awareness of the in-
creased risk of TB among individuals with DM,
Table 3 Predictors for TB detection among individuals with diabetes tested using Xpert MTB/RIF, visiting TB diagnostic and
treatment centers in Karachi, Pakistan (July 2016–July 2018). Significance testing has been done using chi-squared test
Univariate analysis Multivariate analysis
OR 95% CI P value OR 95% CI P value
Gender
Male Ref Ref Ref Ref Ref
Female 1.16 (0.91–1.49) 0.237 1.21 (0.94–1.55) 0.133
Age
Age (years) 1.08 (0.92–1.26) 0.343 0.99 (0.83–1.16) 0.890
Previous History of DM
No previous history (RBS > 200) Ref Ref Ref Ref Ref
Known case of DM 4.58 (3.19–6.59) 0.00 4.63 (3.21–6.66) < 0.0001
Fig. 3 Comparison of HbA1C at baseline and after 3 months of anti-tuberculous treatment at private healthcare clinics in Karachi, Pakistan
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especially in the private sector needs to be therefore ur-
gently addressed. This may be challenging, as unlike TB,
there is no vertical disease program targeting non-
communicable disease (NCDs) in the country. Pakistan
was one of the first low-income countries to formulate a
comprehensive National Action Plan to address NCDs,
but it is yet to be implemented [23]. Training, incentives
for referrals and continuous engagement of private-
practitioners may facilitate TB screening in DM services.
Our study supports the use of chest X-ray for TB
screening in individuals with DM in high TB burden set-
tings. While providers frequently refer patients for
screening for diabetic neuropathy, diabetic nephropathy
and dyslipidemia, TB could be included as an important
complication of diabetes. The use of new technologies
such as computer-aided detection software can facilities
this process. Multi-disciplinary advocacy efforts includ-
ing collaboration with diabetes professional associations
and the pharmaceutical industry are required to increase
awareness of TB-DM co-morbidity, combined with ini-
tiatives by NTPs to target individuals with diabetes as a
high-risk group to be screened.
Limitations
It is likely that providers referred diabetics for TB
screening that had symptoms of TB or had other risk
factors, resulting in selection bias.
The study results may also have been confounded by
other risk factors associated with TB among individuals
with DM such as access to healthcare, level of glycemic
control, compliance with DM medication as well as en-
vironmental factors such as smoking. In addition, we did
not quantify the duration of DM among those screened
for TB.
Conclusion
This study provides evidence for engagement of private
sector in finding missing cases of TB and DM through
systematic bi-directional screening approaches. Given
the high prevalence of undiagnosed DM in TB patients,
there is a need to scale-up the availability of DM testing
and treatment services in TB facilities. A high yield for
TB was identified among diabetics and pre-diabetics in
our study population. There is an urgent need to address
the lack of sensitization among the private providers
about the risk of TB among diabetics, due to which TB
cases among diabetics are frequently missed. Multi-
disciplinary advocacy efforts including collaboration with
diabetes professional associations and the pharmaceut-
ical industry are required to increase awareness of the
TB-DM co-morbidity.
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